115 related articles for article (PubMed ID: 7581115)
1. High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease.
Schwinghammer TL; Bloom EJ; Rosenfeld CS; Wilson JW; Przepiorka D; Shadduck RK
Bone Marrow Transplant; 1995 Jul; 16(1):147-54. PubMed ID: 7581115
[TBL] [Abstract][Full Text] [Related]
2. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.
Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringdén O
Eur J Haematol; 2010 Apr; 84(4):323-31. PubMed ID: 20002156
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
Przepiorka D; Shapiro S; Schwinghammer TL; Bloom EJ; Rosenfeld CS; Shadduck RK; Venkataramanan R
Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
Solomon SR; Nakamura R; Read EJ; Leitman SF; Carter C; Childs R; Dunbar CE; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 May; 31(9):783-8. PubMed ID: 12732885
[TBL] [Abstract][Full Text] [Related]
7. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
9. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
10. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
11. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A
Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
[TBL] [Abstract][Full Text] [Related]
15. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W
Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699
[TBL] [Abstract][Full Text] [Related]
16. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
[TBL] [Abstract][Full Text] [Related]
17. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M
Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
[TBL] [Abstract][Full Text] [Related]
18. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
19. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
Oshima K; Kanda Y; Nakasone H; Arai S; Nishimoto N; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Mar; 83(3):226-32. PubMed ID: 17918253
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
